Results unequivocally support early, aggressive, and sustained risk factor control in patients with complicated type 2 diabetes.
Scott Harris
Advertisement
Articles by Scott Harris
The renal protective effects seen with the SGLT2 inhibitor canogliflizin may be independent of glycemic control, suggest authors of a new post-hoc analysis.
Advertisement
Latest Updated Articles
Intensive Program Extends Lifespan in T2D PatientsSeptember 7th 2016
New Diabetes Drugs May Also Improve Kidney HealthAugust 25th 2016
Advertisement
Advertisement
Trending on Patient Care Online
1
FDA Issues Complete Response Letter for Cingulate ADHD Drug CTx-1301
2
Pediatric Influenza Vaccination Linked to Fewer Diagnoses in Claims Study
3
FDA Approves Xocova as First Oral COVID-19 Postexposure Prophylaxis Option
4
Survey Finds Gaps in US Adult Awareness of HPV, Mpox STI Vaccine Prevention
5